Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.63 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20911008 | 0.92 | RAB9A (0.75) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL12211276 | 0.90 | HPGD (0.58) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL19570478 | 0.89 | RAB9A (0.63) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL7950040 | 0.88 | RAB9A (0.60) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL27599889 | 0.88 | RAB9A (0.60) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL19075405 | 0.88 | RAB9A (0.60) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL18415459 | 0.86 | LMNA (0.66) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL2553685 | 0.84 | HTT (0.65) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL12375168 | 0.83 | MAPK1 (0.70) | RAB9APOLBNPC1MAOBLMNA | |
| SCHEMBL10263540 | 0.83 | HPGD (0.61) | RAB9APOLBNPC1MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486254-B2 | Uracil derivatives for stimulating read-through of premature termination codons | SOUTHERN RESEARCH INSTITUTE (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230416231-A1 | Uracil Derivatives for Stimulating Read-Through of Premature Termination Codons | SOUTHERN RESEARCH INSTITUTE | 2023-12-28 | — | — | US | disclosed |
| WO-2023164246-A1 | URACIL DERIVATIVES FOR STIMULATING READ-THROUGH OF PREMATURE TERMINATION CODONS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-09-19 | — | — | US | disclosed |
| WO-2019073484-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-04-18 | — | — | WO | disclosed |
| EP-2629889-B1 | RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RES & DEV (IL) | 2019-04-03 | — | — | EP | disclosed |
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-04-20 | — | — | US | disclosed |
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-04-20 | — | — | US | disclosed |
| US-20150284417-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-10-08 | — | — | US | disclosed |
| US-20150284417-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-10-08 | — | — | US | disclosed |
| US-9045381-B2 | Ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-06-02 | — | — | US | disclosed |
| US-9045381-B2 | Ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-06-02 | — | — | US | disclosed |
| US-20130281664-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-10-24 | — | — | US | disclosed |
| US-20130281664-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-10-24 | — | — | US | disclosed |
| WO-2012052996-A2 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | ADH1C, ADH5, ADH1A | RAB9A 4054/4885POLB 1451/4885NPC1 4738/4885 |
| US-12486254-B2 | Uracil derivatives for stimulating read-through of premature termination codons | UPF1, UTRN, PURB | RAB9A 964/4885POLB 13/4885NPC1 3607/4885 |
| US-20230416231-A1 | Uracil Derivatives for Stimulating Read-Through of Premature Termination Codons | UPF1, UTRN, PURB | RAB9A 964/4885POLB 13/4885NPC1 3607/4885 |
| US-20150284417-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | ADH1C, ADH5, ADH1A | RAB9A 4054/4885POLB 1451/4885NPC1 4738/4885 |
| US-20130281664-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | ADH5, ADH1C, ADH1A | RAB9A 3970/4885POLB 987/4885NPC1 4697/4885 |
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | CBR3, CBR1, NOX3 | RAB9A 3010/4885POLB 1459/4885NPC1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.